Why the study?
Does percutaneous coronary revascularization with sirolimus-eluting stents improve cost-effectiveness compared to bare metal stents in patients with complex coronary stenoses?
Does percutaneous coronary revascularization with sirolimus-eluting stents improve cost-effectiveness compared to bare metal stents in patients with complex coronary stenoses?
Sirolimus-eluting stents are reasonably cost-effective compared to bare metal stents for complex coronary stenoses within the US healthcare system, despite higher initial costs.
Answers are grounded in this paper and cite their sources.
Sirolimus-eluting stents meet US cost-effectiveness thresholds in complex lesions; extends economic evidence from pivotal randomized trials.
BACKGROUND: Recently, sirolimus-eluting stents (SESs) have been shown to dramatically reduce the risk of angiographic and clinical restenosis compared with bare metal stent (BMS) implantation. However, the overall cost-effectiveness of this strategy is unknown. METHODS AND RESULTS: Between February and August 2001, 1058 patients with complex coronary stenoses were enrolled in the SIRIUS trial and randomized to percutaneous coronary revascularization with either a SES or BMS. Clinical outcomes, resource use, and costs were assessed prospectively for all patients over a 1-year follow-up period. Initial hospital costs were increased by 2881 dollars per patient with SESs. Over the 1-year follow-up period, use of SESs led to substantial reductions in the need for repeat revascularization, including repeat percutaneous coronary intervention and bypass surgery. Although follow-up costs were reduced by 2571 dollars per patient with SESs, aggregate 1-year costs remained 309 dollars per patient higher. The incremental cost-effectiveness ratio for SES was 1650 dollars per repeat revascularization event avoided or 27,540 dollars per quality-adjusted year of life gained, values that compare reasonably with other accepted medical interventions. Under updated treatment assumptions regarding available stent lengths and duration of antiplatelet therapy, use of SESs was projected to reduce total 1-year costs compared with BMSs. CONCLUSIONS: Although use of SESs was not cost-saving compared with BMS implantation, for patients undergoing percutaneous coronary intervention of complex coronary stenoses, their use appears to be reasonably cost-effective within the context of the US healthcare system.
No takes yet. Share an insight, caveat, or question.
Bakhai et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: